Khan SU, Khan MU, Riaz H, et al. - By performing this meta-analysis of 29 randomized controlled trials, researchers determined the influence of body mass index (BMI) on cardiovascular results among patients taking intensive low-density lipoprotein cholesterol (LDL-C) lowering therapy. The included trials were identified from PubMed, Embase and CENTRAL via a search through April 2019. A hazard ratio of 1.07, 1.03, 1.06, 1.08, and 1.04 was reported for cardiovascular mortality, all-cause mortality, myocardial infarction, revascularization, and for MACE, respectively, in relation to more intensive therapy vs less intensive therapy, for every 1 kg/m² rise in BMI, among 265,766 patients. A larger clinical benefit in terms of risk reduction in mortality and cardiovascular outcomes may be seen in patients with normal BMI treated with intensive LDL-C lowering regimens than those with larger BMI. The outcomes could be attributable to a higher mortality rate of obese patients that may artificially lower the effectiveness of treatment, or to a true curative limitation in these patients.